<h4>Methods</h4> We systematically searched PubMed, Embase, and the Cochrane databases for eligible studies assessing the association between PIK3CA mutation and outcomes in patients with HER2-positive breast cancer receiving anti-HER2 therapy. This evidence concerns the gene ERBB2 and breast carcinoma.